Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Recurrent WHO Grade 2 Glioma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 9 of 0 results

Early research (Phase 1)Looking for participantsNCT06964737
What this trial is testing

Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas

Who this might be right for
Recurrent Malignant GliomaRecurrent WHO Grade 3 GliomaRecurrent WHO Grade 4 Glioma+3 more
Ohio State University Comprehensive Cancer Center 30
Testing effectiveness (Phase 2)Looking for participantsNCT05765812
What this trial is testing

Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma

Who this might be right for
Glioblastoma IDH (Isocitrate Dehydrogenase) WildtypeAstrocytoma, Grade III
Debiopharm International SA 116
Testing effectiveness (Phase 2)Study completedNCT02343406
What this trial is testing

Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas

Who this might be right for
Glioblastoma
AbbVie 266
Very early researchStudy completedNCT01678352
What this trial is testing

Imiquimod and Tumor Lysate Vaccine Immunotherapy in Adults With High Risk or Recurrent Grade II Gliomas

Who this might be right for
High Risk WHO Grade II GliomaRecurrent/Post-Chemotherapy WHO Grade II Glioma
Frank Lieberman 19
Testing effectiveness (Phase 2)Active Not RecruitingNCT03212274
What this trial is testing

Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations

Who this might be right for
Advanced Malignant Solid NeoplasmGlioblastomaRecurrent Cholangiocarcinoma+4 more
National Cancer Institute (NCI) 89
Testing effectiveness (Phase 2)Active Not RecruitingNCT04284774
What this trial is testing

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

Who this might be right for
Malignant Solid NeoplasmRecurrent Adrenal Gland PheochromocytomaRecurrent Ectomesenchymoma+38 more
National Cancer Institute (NCI) 5
Early research (Phase 1)Active Not RecruitingNCT03749187
What this trial is testing

BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas

Who this might be right for
GlioblastomaIDH1 Gene MutationIDH2 Gene Mutation+7 more
University of California, San Francisco 78
Early research (Phase 1)Ended earlyNCT04047303
What this trial is testing

CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and Glioblastoma

Who this might be right for
AstrocytomaGlioblastoma
Celgene 20
Early research (Phase 1)Looking for participantsNCT04485559
What this trial is testing

Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)

Who this might be right for
Recurrent World Health Organization (WHO) Grade II GliomaLow-grade GliomaHigh-Grade Glioma (HGG)
University of California, San Francisco 50